Skip to content

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream (Hirudoid) in the Treatment of Cutaneous Dryness: a Prospective, Multi-center, Randomized Controlled Clinical Trial

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream (Hirudoid) in the Treatment of Cutaneous Dryness: a Prospective, Multi-center, Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085574
Enrollment
Unknown
Registered
2024-06-12
Start date
2022-01-31
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin xerosis

Interventions

Test group:Apply mucopolysaccharide polysulfonic acid cream (Hiryosol) twice daily to dry skin areas for 4 weeks
control group:Apply glycerin cream twice daily to dry skin areas for 4 weeks

Sponsors

the First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75, male or female; 2. The clinical diagnosis was skin xerosis, and the ODS of the most severe part was =3; 3. The subject has read the instructions and agrees to sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. The patient is participating or planning to participate in other interventional clinical studies; 2. Allergic to any ingredient in the investigational drug; 3. Patients allergic to heparin, prone to bleeding and known heparin-induced thrombocytopenia; 4. Open wound, damaged skin and mucous membrane; 5. The rash is locally infected with bacteria, viruses and fungi; 6. Pregnant and lactating women or those who were unable to use contraception during the study period; 7. Patients with mental diseases and poor compliance cannot complete the study; 8. Other reasons the researchers considered unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Overall Dry Skin Score, ODS;

Secondary

MeasureTime frame
Visual Analogue Scale, VAS;Transepidermal Water Loss, TEWL;DLQI;

Countries

China

Contacts

Public ContactGao Xinghua

the First Hospital of China Medical University

gaobarry@hotmail.com+86 139 4015 2467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026